- Home
- CYBN vs OKUR Comparison
CYBN vs OKUR Comparison
Compare CYBN & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- OKUR
- Stock Information
- Founded
- CYBN 2019
- OKUR 2011
- Country
- CYBN Canada
- OKUR United States
- Employees
- CYBN N/A
- OKUR N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- OKUR
- Sector
- CYBN Health Care
- OKUR
- Exchange
- CYBN Nasdaq
- OKUR NYSE
- Market Cap
- CYBN 229.8M
- OKUR 234.2M
- IPO Year
- CYBN N/A
- OKUR N/A
- Fundamental
- Price
- CYBN $11.62
- OKUR $16.60
- Analyst Decision
- CYBN Strong Buy
- OKUR Strong Buy
- Analyst Count
- CYBN 3
- OKUR 2
- Target Price
- CYBN $45.50
- OKUR $37.50
- AVG Volume (30 Days)
- CYBN 334.2K
- OKUR 63.1K
- Earning Date
- CYBN 11-13-2024
- OKUR 11-07-2024
- Dividend Yield
- CYBN N/A
- OKUR N/A
- EPS Growth
- CYBN N/A
- OKUR N/A
- EPS
- CYBN N/A
- OKUR N/A
- Revenue
- CYBN N/A
- OKUR N/A
- Revenue This Year
- CYBN N/A
- OKUR N/A
- Revenue Next Year
- CYBN N/A
- OKUR N/A
- P/E Ratio
- CYBN N/A
- OKUR N/A
- Revenue Growth
- CYBN N/A
- OKUR N/A
- 52 Week Low
- CYBN $6.50
- OKUR $9.80
- 52 Week High
- CYBN $21.66
- OKUR $77.60
- Technical
- Relative Strength Index (RSI)
- CYBN 58.44
- OKUR N/A
- Support Level
- CYBN $10.26
- OKUR N/A
- Resistance Level
- CYBN $12.80
- OKUR N/A
- Average True Range (ATR)
- CYBN 1.00
- OKUR 0.00
- MACD
- CYBN 0.05
- OKUR 0.00
- Stochastic Oscillator
- CYBN 60.10
- OKUR 0.00
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.